Exopharm (ASX:EX1)
Company Profile
Exopharm (ASX:EX1) has changed its name to Tryptamine Therapeutics – TYP (ASX: TYP).
Below are the previous articles from Exopharm (ASX:EX1):
RELATED STOCKHEAD STORIES
CLOSING BELL: Corruption? In Africa? Over mining licences? That can’t be right, surely…
CLOSING BELL: ‘How to falter at the last furlong and limp home like a beaten favourite’, by the ASX
ASX February Winners: Semiconductor stocks shine in tough month for investors
Rise and Shine: Everything you need to know before the ASX opens
CLOSING BELL: Forcing the product to pay to be the product is about as Meta as it gets
ASX Small Caps Lunch Wrap: Who wants to watch China pull a CEO out of its hat today?
Rise and Shine: everything you need to know before the ASX opens
Weekly Small Cap and IPO wrap: Large and small caps stumble this week, Omnia Metals due diligence pays off
CLOSING BELL: If everything could just stop blowing up for a while, that’d be great.
Planets align as Exopharm advances its technologies and experts report that exosomes may hold the key to mRNA therapeutics
Exopharm makes big LEAP moving to Phase 2 of collaborative agreement with AIRM
ASX Quarterlies: Nuheara rockets 33pc, Dicker continues to grow, while these biotechs are all cashed up
THE SUNDAY ROAST: The ASX small caps that lit a fire under Stockhead’s experts this week.
